vascular endothelial growth factor

(redirected from Pazopanib)
Also found in: Dictionary, Medical.

vascular endothelial growth factor

[¦vas·kyə·lər ‚en·dō¦thē·lē·əl ′grōth ‚fak·tər]
(medicine)
A soluble factor that acts through specific cell-surface receptors on endothelial cells to critically regulate vasculogenesis.
References in periodicals archive ?
or purchases) dabrafenib, Nilotinib, Everolimus, Lapatinib, Pazopanib, Basiliximab, Mycophenolic acid, Verteporfin and octreotide.
2) He started pazopanib 400 mg daily titrated up to 600 mg daily two weeks later.
However, it would not be useful to have data on tivozanib without being able to compare it with pazopanib and sunitinib, and it is not currently possible to collect the information for pazopanib and sunitinib through the Cancer Drugs Fund.
In PALETTE study, Pazopanib revealed a 3-month benefit in progression-free survival in patients with nonadipocytic sarcomas [6].
Pazopanib (Votrient[R]) is an oral medication that interferes with angiogenesis.
Recently approved drugs for the treatment of kidney cancer include sorafenib (2005), sunitinib (2006), temsirolimus (2007) everolimus (2009), bevacizumab (2009) and pazopanib (2009).
In recent years, several molecularly targeted therapies such as sunitinib, sorafenib, and pazopanib, which target the receptor tyrosine kinases of VEGF have been approved for CCRCC.
Pazopanib at a daily dose of 800 mg, orally, may produce liver toxicity and prolongation of the QT interval (25-27).
The manufacturer has offered a straight discount on the list price, as well as providing a possible future rebate linked to the outcome of the head-to-head trial comparing pazopanib and sunitinib; making pazopanib a cost-effective option for the NHS.
The National Comprehensive Cancer Network (NCCN) has been awarded two individual $2 million grants from GlaxoSmithKline (GSK) to support clinical studies of ofatumumab (Arzerra(R), GlaxoSmithKline) in the treatment of hematologic malignancies and pazopanib (Votrient(R), GlaxoSmithKline) in the treatment of solid tumors.
The four antineoplastics are everolimus (Afinitor; D), a protein-tyrosine kinase inhibitor for advanced renal cell carcinoma; ofatumumab (Arzerra; C), a monoclonal antibody for chronic lymphocytic leukemia; pazopanib (Votrient; D), a tyrosine kinase inhibitor for advanced renal cell carcinoma; and romidepsin (Istodax; D), a histone deacetylase inhibitor for cutaneous T-cell lymphoma.
Specific topics include the discovery of Pazopanib as a pan-vascular endothelial growth factor kinase inhibitor, the structure-based design and characterization of Axitinib; allosteric MEK inhibitors, PHA-793958, GSK461364 as a polo-like kinase-one inhibitor for treating cancer, the practical use of computational chemistry in kinase drug discovery, and approaches to kinase homology modeling.